{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Undifferentiated+Pleomorphic+Sarcoma", "query": { "condition": "Advanced Undifferentiated Pleomorphic Sarcoma" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 33, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Undifferentiated+Pleomorphic+Sarcoma&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-05-22T04:49:40.603Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05827614", "title": "Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Triple Negative Breast Cancer (TNBC)", "High Grade Serous Ovarian Carcinoma", "High Grade Endometrial Carcinoma", "Anogenital Cancer", "Head and Neck (HNSCC)", "Cutaneous Squamous Cell Carcinoma (CSCC)", "Cervical Squamous Cell Carcinoma", "ER+ Breast Cancer", "Leiomyosarcoma (LMS)", "Undifferentiated Pleomorphic Sarcoma (UPS)", "Pancreatic Cancer Metastatic", "Small Cell Lung Cancer" ], "interventions": [ { "name": "BBI-355", "type": "DRUG" }, { "name": "Erlotinib", "type": "DRUG" }, { "name": "Futibatinib", "type": "DRUG" }, { "name": "BBI-825", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boundless Bio, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 85, "start_date": "2023-03-24", "completion_date": "2027-03-31", "has_results": false, "last_update_posted_date": "2026-01-23", "last_synced_at": "2026-05-22T04:49:40.603Z", "location_count": 16, "location_summary": "Los Angeles, California • Santa Monica, California • Denver, Colorado + 12 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Lake Mary", "state": "Florida" }, { "city": "Fairway", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05827614" }, { "nct_id": "NCT05836571", "title": "Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Locally Advanced Extraskeletal Myxoid Chondrosarcoma", "Locally Advanced Leiomyosarcoma", "Locally Advanced Liposarcoma", "Locally Advanced Undifferentiated Pleomorphic Sarcoma", "Locally Advanced Unresectable Soft Tissue Sarcoma", "Metastatic Soft Tissue Sarcoma", "Metastatic Undifferentiated Pleomorphic Sarcoma", "Unresectable Leiomyosarcoma", "Unresectable Liposarcoma", "Unresectable Undifferentiated Pleomorphic Sarcoma" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Cabozantinib", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute LAO", "sponsor_class": "UNKNOWN", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 66, "start_date": "2023-10-25", "completion_date": "2026-05-15", "has_results": false, "last_update_posted_date": "2026-04-21", "last_synced_at": "2026-05-22T04:49:40.603Z", "location_count": 26, "location_summary": "Duarte, California • Irvine, California • Los Angeles, California + 19 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05836571" }, { "nct_id": "NCT04099277", "title": "A Study of LY3435151 in Participants With Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor", "Triple-negative Breast Cancer", "Gastric Adenocarcinoma", "Head and Neck Squamous Cell Carcinoma", "Cervical Carcinoma", "High Grade Serous Ovarian Carcinoma", "Hepatocellular Carcinoma", "Undifferentiated Pleomorphic Sarcoma", "Leiomyosarcoma" ], "interventions": [ { "name": "LY3435151", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2019-10-28", "completion_date": "2020-03-05", "has_results": true, "last_update_posted_date": "2021-08-31", "last_synced_at": "2026-05-22T04:49:40.603Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04099277" }, { "nct_id": "NCT02451943", "title": "A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Soft Tissue Sarcoma" ], "interventions": [ { "name": "Olaratumab", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 509, "start_date": "2015-09-14", "completion_date": "2024-06-27", "has_results": true, "last_update_posted_date": "2025-07-15", "last_synced_at": "2026-05-22T04:49:40.603Z", "location_count": 30, "location_summary": "Duarte, California • Los Angeles, California • Stanford, California + 20 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02451943" }, { "nct_id": "NCT05116800", "title": "Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Soft Tissue Sarcoma", "Undifferentiated Pleomorphic Sarcoma", "Myxofibrosarcoma", "Leiomyosarcoma", "Liposarcoma", "Angiosarcoma", "Synovial Sarcoma", "Rhabdomyosarcoma", "Spindle Cell Sarcoma", "High Grade Sarcoma", "Bone Sarcoma", "Osteosarcoma", "Ewing Sarcoma of Bone" ], "interventions": [ { "name": "Gemcitabine", "type": "DRUG" }, { "name": "9-ING-41", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Brown University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "10 Years", "maximum_age": null, "sex": "ALL", "summary": "10 Years and older" }, "enrollment_count": 0, "start_date": "2022-03-01", "completion_date": "2030-08", "has_results": false, "last_update_posted_date": "2021-12-07", "last_synced_at": "2026-05-22T04:49:40.603Z", "location_count": 2, "location_summary": "Providence, Rhode Island", "locations": [ { "city": "Providence", "state": "Rhode Island" }, { "city": "Providence", "state": "Rhode Island" } ], "official_url": "https://clinicaltrials.gov/study/NCT05116800" }, { "nct_id": "NCT03425279", "title": "CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Undifferentiated Pleomorphic Sarcoma", "Myxofibrosarcoma" ], "interventions": [ { "name": "CAB-AXL-ADC", "type": "BIOLOGICAL" }, { "name": "PD-1 inhibitor", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "BioAtla, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 245, "start_date": "2018-02-15", "completion_date": "2025-01-08", "has_results": false, "last_update_posted_date": "2025-09-23", "last_synced_at": "2026-05-22T04:49:40.603Z", "location_count": 35, "location_summary": "Tucson, Arizona • Los Angeles, California • San Francisco, California + 24 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03425279" }, { "nct_id": "NCT01189253", "title": "Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Sarcoma" ], "interventions": [ { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "trabectedin", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "quality-of-life assessment", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "OTHER", "PROCEDURE" ], "sponsor": "European Organisation for Research and Treatment of Cancer - EORTC", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 133, "start_date": "2011-05", "completion_date": "2015-06", "has_results": false, "last_update_posted_date": "2014-08-08", "last_synced_at": "2026-05-22T04:49:40.603Z", "location_count": 8, "location_summary": "Santa Monica, California • Stanford, California • Iowa City, Iowa + 4 more", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01189253" }, { "nct_id": "NCT04906876", "title": "A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Sarcoma", "Soft Tissue Sarcoma", "Metastatic Sarcoma", "Undifferentiated Pleomorphic Sarcoma", "Myxofibrosarcoma", "Leiomyosarcoma", "Liposarcoma", "Angiosarcoma", "Synovial Sarcoma", "Rhabdomyosarcoma", "Spindle Cell Sarcoma", "High Grade Sarcoma", "Bone Sarcoma" ], "interventions": [ { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "9-ING-41", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Brown University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "10 Years", "maximum_age": null, "sex": "ALL", "summary": "10 Years and older" }, "enrollment_count": 0, "start_date": "2021-09", "completion_date": "2025-07", "has_results": false, "last_update_posted_date": "2021-07-28", "last_synced_at": "2026-05-22T04:49:40.603Z", "location_count": 2, "location_summary": "Providence, Rhode Island", "locations": [ { "city": "Providence", "state": "Rhode Island" }, { "city": "Providence", "state": "Rhode Island" } ], "official_url": "https://clinicaltrials.gov/study/NCT04906876" }, { "nct_id": "NCT04242238", "title": "Study of DCC-3014 in Combination With Avelumab in Patients With Advanced or Metastatic Sarcomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Sarcoma", "Advanced Sarcoma", "High Grade Sarcoma", "Leiomyosarcoma", "Undifferentiated Pleomorphic Sarcoma", "Myxofibrosarcoma", "Dedifferentiated Liposarcoma" ], "interventions": [ { "name": "DCC-3014", "type": "DRUG" }, { "name": "Avelumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2020-01-22", "completion_date": "2025-08-26", "has_results": false, "last_update_posted_date": "2025-08-28", "last_synced_at": "2026-05-22T04:49:40.603Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04242238" }, { "nct_id": "NCT02601209", "title": "Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "High Grade Sarcoma", "Metastatic Leiomyosarcoma", "Metastatic Malignant Peripheral Nerve Sheath Tumor", "Metastatic Synovial Sarcoma", "Metastatic Undifferentiated Pleomorphic Sarcoma", "Metastatic Unresectable Sarcoma", "Myxofibrosarcoma", "Recurrent Leiomyosarcoma", "Recurrent Malignant Peripheral Nerve Sheath Tumor", "Recurrent Synovial Sarcoma", "Recurrent Undifferentiated Pleomorphic Sarcoma", "Stage III Uterine Corpus Leiomyosarcoma AJCC v8", "Stage IIIA Uterine Corpus Leiomyosarcoma AJCC v8", "Stage IIIB Uterine Corpus Leiomyosarcoma AJCC v8", "Stage IIIC Uterine Corpus Leiomyosarcoma AJCC v8", "Stage IV Uterine Corpus Leiomyosarcoma AJCC v8", "Stage IVA Uterine Corpus Leiomyosarcoma AJCC v8", "Stage IVB Uterine Corpus Leiomyosarcoma AJCC v8", "Unresectable Leiomyosarcoma" ], "interventions": [ { "name": "Pazopanib", "type": "DRUG" }, { "name": "Pazopanib Hydrochloride", "type": "DRUG" }, { "name": "Sapanisertib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 151, "start_date": "2015-11-30", "completion_date": "2022-07-11", "has_results": true, "last_update_posted_date": "2022-08-23", "last_synced_at": "2026-05-22T04:49:40.603Z", "location_count": 460, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 286 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT02601209" } ] }